Radboud UMC Nijmegen

Glycostem and Radboud UMC partnered in preclinical and clinical research.

During a four year project period Glycostem has successfully established the translation "from bench to bedside" of oNKord® together with collaborating partners at RadboudUMC in Nijmegen, the Netherlands. After an initial phase of preclinical research to improve treatment of AML, the technology has been successfully transferred into a phase I clinical trial to use NK cells in elderly patients in AML.

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.